Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
A critical step for the future development of an artificial pancreas for diabetics and hypogycemics has been launched by Medtronic, Inc. (NYSE:MDT). Medtronic, located in Minneapolis, just finished the first enrollment of patients for an experimental device exemption (IDE) clinical trial of its innovation Predictive Low Glucose Management (PLGM) technology.
Medtronic, a global leader in medical technology, will perform a clinical trial to evaluate the safety of its next-generation integrated insulin pump and continuous glucose monitoring (CGM) system, the only technology available in the U.S, which works by sensing the glucose levels and starting insulin delivery when an acceptable minimum value is reached.
http://diabetesnewsjournal.com/2014...predictive-low-glucose-management-technology/
Medtronic, a global leader in medical technology, will perform a clinical trial to evaluate the safety of its next-generation integrated insulin pump and continuous glucose monitoring (CGM) system, the only technology available in the U.S, which works by sensing the glucose levels and starting insulin delivery when an acceptable minimum value is reached.
http://diabetesnewsjournal.com/2014...predictive-low-glucose-management-technology/